Top

Published in:

01-05-2015 | 2014 SSAT Plenary Presentation

The Durability of Endoscopic Therapy for Treatment of Barrett’s Metaplasia, Dysplasia, and Mucosal Cancer After Nissen Fundoplication

Authors: Corey S. Johnson, Brian E. Louie, Aaron Wille, Christy M. Dunst, Stephanie G. Worrell, Steven R. DeMeester, Jessica Reynolds, Joe Dixon, John C. Lipham, Michal Lada, Jeffrey H. Peters, Thomas J. Watson, Alexander S. Farivar, Ralph W. Aye

Published in: Journal of Gastrointestinal Surgery | Issue 5/2015

Abstract

Introduction

Radiofrequency ablation (RFA) ± endoscopic resection (EMR) is an established treatment strategy for neoplastic Barrett’s and intramucosal cancer. Most patients are managed with proton pump inhibitors. The incidence of recurrent Barrett’s metaplasia, dysplasia, or cancer after complete eradication is up to 43 % using this strategy. We hypothesize the addition of fundoplication should result in a lower recurrence rates after complete eradication.

Methods

Multi-institutional retrospective review of patients undergoing endotherapy followed by Nissen fundoplication

Results

A total of 49 patients underwent RFA ± EMR followed by Nissen fundoplication. Complete remission of intestinal metaplasia (CR-IM) was achieved in 26 (53 %) patients, complete remission of dysplasia (CR-D) in 16 (33 %) patients, and 7 (14 %) had persistent neoplastic Barrett’s. After fundoplication, 18/26 (70 %) remained in CR-IM. An additional 10/16 CR-D achieved CR-IM and 4/7 with persistent dysplasia achieved CR-IM. One patient progressed to LGD while no patient developed HGD or cancer.

Conclusion

Endoscopic therapy for Barrett’s dysplasia and/or intramucosal cancer followed by fundoplication results in similar durability of CR-IM to patients being managed with PPIs alone after endoscopic therapy. However, fundoplication may be superior in preventing further progression of disease and the development of cancer. Fundoplication is an important strategy to achieve and maintain CR-IM, and facilitate eradication of persistent dysplasia.

Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency Ablation in Barrett’s Esophagus With Dysplasia. N Engl J Med. 2009 May 28;360(22):2277–88.

Pouw RE, Wirths K, Eisendrath P, Sondermeijer CM, Ten Kate FJ, Fockens P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol. Elsevier Inc.; 2010 Jan;8(1):23–9.

Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013 Jul;145(1):87–95.

Gupta M, Iyer PG, Lutzke L, Gorospe EC, Abrams J a, Falk GW, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology. Elsevier, Inc; 2013 Jul;145(1):79–86.e1.

Guarner-Argente C, Buoncristiano T, Furth EE, Falk GW, Ginsberg GG. Long-term outcomes of patients with Barrett’s esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc. Elsevier Inc.; 2013 Feb;77(2):190–9.

Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. Gastroenterology. 2011 Aug;141(2):460–8.

Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett’s esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. Elsevier Inc.; 2012 Sep;143(3):576–81.

Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, et al. Long-Term Results of a Randomized Prospective Study Comparing Medical and Surgical Treatment of Barrett’s Esophagus. Ann Surg. 2003 Mar;237(3):291–8.

Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole. Gastroenterology. 2001 Jun;120(7):1599–606.

10.

Theodorou D, Ayazi S, DeMeester SR, Zehetner J, Peyre CG, Grant KS, et al. Intraluminal pH and goblet cell density in Barrett’s esophagus. J Gastrointest Surg. 2012 Mar;16(3):469–74.

11.

Smith E, Kelly JJ, Ruskiewicz AR, Sullivan T, Jamieson GG, Drew P a. The effect of long-term control of reflux by fundoplication on aberrant deoxyribonucleic acid methylation in patients with Barrett esophagus. Ann Surg. 2010 Jul;252(1):63–9.

12.

O’Connell K, Velanovich V. Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus. Surg Endosc. 2011 Mar;25(3):830–4.

13.

Shaheen NJ, Kim HP, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, et al. Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry. J Gastrointest Surg. 2013 Jan;17(1):21–8; discussion p.28–9.

14.

Hunt BM, Louie BE, Schembre DB, Bohorfoush AG, Farivar AS, Aye RW. Outcomes in Patients Who Have Failed Endoscopic Therapy for Dysplastic Barrett’s Metaplasia or Early Esophageal Cancer. Ann Thorac Surg. 2013 May 2;95(5):1734–40.

15.

Zehetner J, DeMeester SR, Hagen J a, Ayazi S, Augustin F, Lipham JC, et al. Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma. J Thorac Cardiovasc Surg. 2011 Jan;141(1):39–47.

16.

Lada M, Watson TJ, Shakoor A, Nieman DR, Han M, Tschoner A, et al. Eliminating a Need for Esophagectomy: Endoscopic Treatment of Barrett’s Esophagus with Early Esophageal Neoplasia. J Thorac Cardiovasc. 2014;In press.

17.

Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’sesophagus. Gastroenterology 1993;105:40–50.PubMed

18.

Bulsiewicz WJ, Dellon ES, Lyday WD, Ertan A, Camara DS, Komanduri S, et al. Predictors of recurrent Barret’s esophagus after successful ablation in a nationwide, multicenter cohort: Results from the U.S. RFA Registry. Gastroenterology. 2013;144(S-1).

19.

Phoa KN, Pouw RE, van Vilsteren FGI, Sondermeijer CMT, Ten Kate FJW, Visser M, et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. Elsevier, Inc; 2013 Jul;145(1):96–104.

20.

Corley DA. Can You Stop Surveillance After Radiofrequency Ablation of Barrett’s Esophagus? A Glass Half Full. Gastroenterology. 2013 Jul;145(1):39–42.

21.

Fleischer DE, Odze R, Overholt BF, Carroll J, Chang KJ, Das A, et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett’s esophagus. Dig Dis Sci. 2010 Jul;55(7):1918–31.

22.

Vallböhmer D, DeMeester SR, Oh DS, Banki F, Kuramochi H, Shimizu D, et al. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol. 2006 Jul;101(7):1458–66.

23.

Vallböhmer D, DeMeester SR, Peters JH, Oh DS, Kuramochi H, Shimizu D, et al. Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus. Dis Esophagus. 2006 Jan;19(4):260–6.

24.

Chang EY, Morris CD, Seltman AK, O’Rourke RW, Chan BK, Hunter JG, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg. 2007 Jul;246(1):11–21.

25.

Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol. 2003 Nov;98(11):2390–4.

26.

Vakil N. Review article: the role of surgery in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007 Jun 15;25(12):1365–72.

27.

Shen KR, Harrison-Phipps KM, Cassivi SD, Wigle D, Nichols FC, Allen MS, et al. Esophagectomy after anti-reflux surgery. J Thorac Cardiovasc Surg. United States; 2010 Apr;139(4):969–75.

28.

Chang AC, Lee JS, Sawicki KT, Pickens A, Orringer MB. Outcomes after esophagectomy in patients with prior antireflux or hiatal hernia surgery. Ann Thorac Surg. Elsevier Inc.; 2010 Apr;89(4):1015–21; discussion 1022–3.

Title: The Durability of Endoscopic Therapy for Treatment of Barrett’s Metaplasia, Dysplasia, and Mucosal Cancer After Nissen Fundoplication
Authors: Corey S. Johnson
Brian E. Louie
Aaron Wille
Christy M. Dunst
Stephanie G. Worrell
Steven R. DeMeester
Jessica Reynolds
Joe Dixon
John C. Lipham
Michal Lada
Jeffrey H. Peters
Thomas J. Watson
Alexander S. Farivar
Ralph W. Aye
Publication date: 01-05-2015
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 5/2015
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-015-2783-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Durability of Endoscopic Therapy for Treatment of Barrett’s Metaplasia, Dysplasia, and Mucosal Cancer After Nissen Fundoplication

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2015

Pre-surgical Geriatric Syndromes, Frailty, and Risks for Postoperative Delirium in Older Patients Undergoing Gastrointestinal Surgery: Prevalence and Red Flags

Novel Jejunoduodenostomy Technique for Prevention of Duodenal Stump Blowout Following Gastrectomy

Current Status of Management of Malignant Disease: Current Management of Esophageal Cancer

Minimally Invasive Resection of Choledochal Cyst: a Feasible and Safe Surgical Option

Conduit Vascular Evaluation is Associated with Reduction in Anastomotic Leak After Esophagectomy

Anterior Hepatic Parenchymal Transection for Complete Caudate Lobectomy to Treat Liver Cancer Situated in or Involving the Paracaval Portion of the Caudate Lobe